Search

Displaying results 591 - 600 of 10000 in total
  1. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. … Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.

    Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsSynonyms: DL-ketamine
  2. Drug

    Trimebutine

    go.drugbank.com/drugs/DB09089
    ApprovedInvestigational

    Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries. … It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form.

    International brands: Ni Wei Fu, Shuang DiProducts: COLYPAN ®300 MG TABLETAS DE LIBERACION PROLONGADA, TRIMEBUTINA MALEATO 300 MG TABLETA DE LIBERACIÓN PROLONGADA
  3. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol

    Products: FEBUXOSTAT DOC GENERICI, Febuxostat Genericon 80 mg Filmtabletten
  4. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].

    Mixtures: ARGLIPTIN-D, LIBERECO-DXCategories: Drugs Used in Diabetes, DPP-IV Inhibitors
  5. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … It was originally approved by the U.S.

    Products: MABTHERA ® CONCENTRADO DE SOLUCIÓN PARA INFUSIÓN 500 MG / 50 ML, TRUXİMA 500 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET
  6. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography. … It is used in adult and in pediatric patients over the age of 6 years with chronic kidney disease (CKD) receiving hemodialysis and receiving supplemental epoetin therapy.

    Products: Sodium Ferric Gluconate Complex in Sucrose
  7. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.

    Products: XELJANZ® XR 11 MG TABLETAS DE LIBERACIÓN MODIFICADA
  8. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    [L32853] An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. … use alongside solifenacin in refractory cases.

    Products: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADA
  9. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

    Synonyms: DL-Baclofen, DL-4-Amino-3-p-chlorophenylbutanoic acidProducts: BACLENO® 10MG/5ML SOLUCIÓN DE PERFUSIÓN, BACLOFENE MYLAN GENERICS
  10. Drug

    Hydroxyethyl Starch

    go.drugbank.com/drugs/DB09106
    ApprovedInvestigational

    HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose. … Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume.

    Mixtures: Hydroxyethyl Starch in Sodium Chloride, HYPERHAES INT. INF. ICIN COZELTICategories: Compounds used in a research, industrial, or household setting